On the morning of April 25, a delegation led by Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League and Chairman of the All-China Youth Federation, visited CTTQ, a core enterprise of Sino Biopharmaceutical (1177.HK), for inspection and guidance. The visit focused on pharmaceutical technology innovation, digital and intelligent transformation, and youth talent cultivation, aiming to empower and encourage the company's high-quality development. Eric Tse, Chief Executive Officer of Sino Biopharmaceutical, Chairman of Chia Tai Tianqing, and a member of the All-China Youth Federation, accompanied the inspection and introduced the company's innovative development. 

At the CTTQ Digital Intelligence Future Experience Center, the delegation gained a comprehensive understanding of the company's development history, industrial layout, and innovative achievements. Among the many innovative achievements, the company's independently developed "Defu Combination" targeted-immuno combination therapy has attracted significant attention. This regimen breaks through the limitations of traditional treatments, achieving a synergistic effect of "1+1>2". It has been successively approved for four clinically recognized refractory diseases: endometrial cancer, extensive-stage small cell lung cancer, renal cell carcinoma, and alveolar soft tissue sarcoma, bringing new hope to a broad range of cancer patients. 

Subsequently, the delegation visited the CTTQ Research Institute to learn firsthand about the construction of cutting-edge R&D platforms. The company has established 6 core technology platforms, enabling full-chain empowerment from drug discovery to industrialization. Leveraging its independently built AI drug discovery platform, the company has shortened the preclinical candidate compound (PCC) discovery cycle by more than 50%, significantly improving R&D efficiency. Two new-generation protein degraders developed with the platform's assistance have best-in-class potential, showcasing the company's strong R&D capabilities in cutting-edge technology fields. 

In the biologics production workshop, the intelligent, large-scale, and domesticated macromolecule biologic drug production lines left a deep impression on the delegation. CTTQ's biologic drug production lines have a capacity of 86,000L, including six 10,000L scale production lines. The company has taken the lead in China in achieving full-chain domestic substitution for key equipment and core materials, while also deeply integrating AI technology to empower production and operations. Currently, CTTQ has received marketing approval for more than 10 macromolecule biologic drugs, and its comprehensive strength is firmly ranked among the top in the domestic biopharmaceutical industry. 

With the May Fourth Youth Day approaching, the delegation also paid special attention to the company's work in cultivating young talent. CTTQ currently has over 13,000 employees, with 77.3% being under the age of 35, forming the backbone of the company's development. With Tianqing University as its core platform, the company has built a training system covering the entire career cycle and created benchmark talent projects such as "Leadership Star · Star Youth" and the "π-Leap Program." This provides young employees with systematic training and diverse development pathways, allowing young talent to showcase their abilities and grow on the front lines of technological innovation. 

Zhang Yongyi, Deputy Secretary of the Jiangsu Provincial Committee of the Communist Youth League and Chairman of the Jiangsu Youth Federation, and Shi Lei, Secretary of the Nanjing Municipal Committee of the Communist Youth League and Chairman of the Nanjing Youth Federation, were among those accompanying the inspection. 

Declaration:

The copyright of this article is owned by the original author or the Company. It may not be used by reprinting, copying, filming, adapting, compiling, or other means without authorization. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.